nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—Alopecia reversible—Epirubicin—thyroid cancer	0.0273	0.0273	CcSEcCtD
Nadolol—Respiratory distress—Sorafenib—thyroid cancer	0.0264	0.0264	CcSEcCtD
Nadolol—Alopecia reversible—Doxorubicin—thyroid cancer	0.0252	0.0252	CcSEcCtD
Nadolol—Oropharyngeal discomfort—Sorafenib—thyroid cancer	0.023	0.023	CcSEcCtD
Nadolol—Dry eye—Vandetanib—thyroid cancer	0.0229	0.0229	CcSEcCtD
Nadolol—Cardiac failure—Vandetanib—thyroid cancer	0.0185	0.0185	CcSEcCtD
Nadolol—Lethargy—Vandetanib—thyroid cancer	0.0184	0.0184	CcSEcCtD
Nadolol—Cardiomegaly—Epirubicin—thyroid cancer	0.017	0.017	CcSEcCtD
Nadolol—Dry skin—Vandetanib—thyroid cancer	0.0165	0.0165	CcSEcCtD
Nadolol—Gastritis—Vandetanib—thyroid cancer	0.0159	0.0159	CcSEcCtD
Nadolol—Cardiomegaly—Doxorubicin—thyroid cancer	0.0157	0.0157	CcSEcCtD
Nadolol—Bronchospasm—Vandetanib—thyroid cancer	0.0153	0.0153	CcSEcCtD
Nadolol—Depression—Vandetanib—thyroid cancer	0.0138	0.0138	CcSEcCtD
Nadolol—Conjunctivitis—Vandetanib—thyroid cancer	0.0135	0.0135	CcSEcCtD
Nadolol—Cardiac failure congestive—Sorafenib—thyroid cancer	0.0134	0.0134	CcSEcCtD
Nadolol—Bradycardia—Vandetanib—thyroid cancer	0.0127	0.0127	CcSEcCtD
Nadolol—Cardiac failure—Sorafenib—thyroid cancer	0.0125	0.0125	CcSEcCtD
Nadolol—Visual impairment—Vandetanib—thyroid cancer	0.012	0.012	CcSEcCtD
Nadolol—Mood swings—Sorafenib—thyroid cancer	0.0115	0.0115	CcSEcCtD
Nadolol—Dry skin—Sorafenib—thyroid cancer	0.0111	0.0111	CcSEcCtD
Nadolol—Alopecia—Vandetanib—thyroid cancer	0.011	0.011	CcSEcCtD
Nadolol—Gastritis—Sorafenib—thyroid cancer	0.0108	0.0108	CcSEcCtD
Nadolol—Vision blurred—Vandetanib—thyroid cancer	0.0102	0.0102	CcSEcCtD
Nadolol—Abdominal discomfort—Sorafenib—thyroid cancer	0.0101	0.0101	CcSEcCtD
Nadolol—Erectile dysfunction—Sorafenib—thyroid cancer	0.00968	0.00968	CcSEcCtD
Nadolol—Loss of consciousness—Vandetanib—thyroid cancer	0.00954	0.00954	CcSEcCtD
Nadolol—Cough—Vandetanib—thyroid cancer	0.00947	0.00947	CcSEcCtD
Nadolol—Hypertension—Vandetanib—thyroid cancer	0.00937	0.00937	CcSEcCtD
Nadolol—Chest pain—Vandetanib—thyroid cancer	0.00924	0.00924	CcSEcCtD
Nadolol—Dry mouth—Vandetanib—thyroid cancer	0.00903	0.00903	CcSEcCtD
Nadolol—Oedema—Vandetanib—thyroid cancer	0.00886	0.00886	CcSEcCtD
Nadolol—Insomnia—Vandetanib—thyroid cancer	0.00801	0.00801	CcSEcCtD
Nadolol—Paraesthesia—Vandetanib—thyroid cancer	0.00795	0.00795	CcSEcCtD
Nadolol—Dyspnoea—Vandetanib—thyroid cancer	0.0079	0.0079	CcSEcCtD
Nadolol—Tinnitus—Sorafenib—thyroid cancer	0.00784	0.00784	CcSEcCtD
Nadolol—Dyspepsia—Vandetanib—thyroid cancer	0.0078	0.0078	CcSEcCtD
Nadolol—Decreased appetite—Vandetanib—thyroid cancer	0.0077	0.0077	CcSEcCtD
Nadolol—Fatigue—Vandetanib—thyroid cancer	0.00764	0.00764	CcSEcCtD
Nadolol—Constipation—Vandetanib—thyroid cancer	0.00757	0.00757	CcSEcCtD
Nadolol—Pain—Vandetanib—thyroid cancer	0.00757	0.00757	CcSEcCtD
Nadolol—Alopecia—Sorafenib—thyroid cancer	0.00743	0.00743	CcSEcCtD
Nadolol—Body temperature increased—Vandetanib—thyroid cancer	0.007	0.007	CcSEcCtD
Nadolol—Ventricular extrasystoles—Epirubicin—thyroid cancer	0.00685	0.00685	CcSEcCtD
Nadolol—Syncope—Sorafenib—thyroid cancer	0.00656	0.00656	CcSEcCtD
Nadolol—Dysarthria—Epirubicin—thyroid cancer	0.00654	0.00654	CcSEcCtD
Nadolol—Loss of consciousness—Sorafenib—thyroid cancer	0.00643	0.00643	CcSEcCtD
Nadolol—Cough—Sorafenib—thyroid cancer	0.00639	0.00639	CcSEcCtD
Nadolol—Atrioventricular block—Epirubicin—thyroid cancer	0.00638	0.00638	CcSEcCtD
Nadolol—Asthenia—Vandetanib—thyroid cancer	0.00635	0.00635	CcSEcCtD
Nadolol—Ventricular extrasystoles—Doxorubicin—thyroid cancer	0.00634	0.00634	CcSEcCtD
Nadolol—Hypertension—Sorafenib—thyroid cancer	0.00632	0.00632	CcSEcCtD
Nadolol—Pruritus—Vandetanib—thyroid cancer	0.00627	0.00627	CcSEcCtD
Nadolol—Dry mouth—Sorafenib—thyroid cancer	0.00609	0.00609	CcSEcCtD
Nadolol—Diarrhoea—Vandetanib—thyroid cancer	0.00606	0.00606	CcSEcCtD
Nadolol—Dysarthria—Doxorubicin—thyroid cancer	0.00605	0.00605	CcSEcCtD
Nadolol—Atrioventricular block—Doxorubicin—thyroid cancer	0.0059	0.0059	CcSEcCtD
Nadolol—Shock—Sorafenib—thyroid cancer	0.00588	0.00588	CcSEcCtD
Nadolol—Fluid retention—Epirubicin—thyroid cancer	0.00587	0.00587	CcSEcCtD
Nadolol—Dizziness—Vandetanib—thyroid cancer	0.00586	0.00586	CcSEcCtD
Nadolol—Dry eye—Epirubicin—thyroid cancer	0.00572	0.00572	CcSEcCtD
Nadolol—Anorexia—Sorafenib—thyroid cancer	0.00569	0.00569	CcSEcCtD
Nadolol—Vomiting—Vandetanib—thyroid cancer	0.00563	0.00563	CcSEcCtD
Nadolol—Rash—Vandetanib—thyroid cancer	0.00558	0.00558	CcSEcCtD
Nadolol—Dermatitis—Vandetanib—thyroid cancer	0.00558	0.00558	CcSEcCtD
Nadolol—Pulmonary oedema—Epirubicin—thyroid cancer	0.00551	0.00551	CcSEcCtD
Nadolol—Fluid retention—Doxorubicin—thyroid cancer	0.00544	0.00544	CcSEcCtD
Nadolol—Dyspnoea—Sorafenib—thyroid cancer	0.00533	0.00533	CcSEcCtD
Nadolol—Dry eye—Doxorubicin—thyroid cancer	0.00529	0.00529	CcSEcCtD
Nadolol—Nausea—Vandetanib—thyroid cancer	0.00526	0.00526	CcSEcCtD
Nadolol—Dyspepsia—Sorafenib—thyroid cancer	0.00526	0.00526	CcSEcCtD
Nadolol—Decreased appetite—Sorafenib—thyroid cancer	0.00519	0.00519	CcSEcCtD
Nadolol—Fatigue—Sorafenib—thyroid cancer	0.00515	0.00515	CcSEcCtD
Nadolol—Pain—Sorafenib—thyroid cancer	0.00511	0.00511	CcSEcCtD
Nadolol—Constipation—Sorafenib—thyroid cancer	0.00511	0.00511	CcSEcCtD
Nadolol—Pulmonary oedema—Doxorubicin—thyroid cancer	0.0051	0.0051	CcSEcCtD
Nadolol—Cardiac failure congestive—Epirubicin—thyroid cancer	0.00495	0.00495	CcSEcCtD
Nadolol—Body temperature increased—Sorafenib—thyroid cancer	0.00472	0.00472	CcSEcCtD
Nadolol—Cardiac failure—Epirubicin—thyroid cancer	0.0046	0.0046	CcSEcCtD
Nadolol—Lethargy—Epirubicin—thyroid cancer	0.00458	0.00458	CcSEcCtD
Nadolol—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.00458	0.00458	CcSEcCtD
Nadolol—Diplopia—Epirubicin—thyroid cancer	0.00449	0.00449	CcSEcCtD
Nadolol—Affect lability—Epirubicin—thyroid cancer	0.00442	0.00442	CcSEcCtD
Nadolol—Asthenia—Sorafenib—thyroid cancer	0.00429	0.00429	CcSEcCtD
Nadolol—Cardiac failure—Doxorubicin—thyroid cancer	0.00426	0.00426	CcSEcCtD
Nadolol—Mood swings—Epirubicin—thyroid cancer	0.00426	0.00426	CcSEcCtD
Nadolol—Lethargy—Doxorubicin—thyroid cancer	0.00424	0.00424	CcSEcCtD
Nadolol—Pruritus—Sorafenib—thyroid cancer	0.00423	0.00423	CcSEcCtD
Nadolol—Diplopia—Doxorubicin—thyroid cancer	0.00416	0.00416	CcSEcCtD
Nadolol—Dry skin—Epirubicin—thyroid cancer	0.00412	0.00412	CcSEcCtD
Nadolol—Affect lability—Doxorubicin—thyroid cancer	0.00409	0.00409	CcSEcCtD
Nadolol—Diarrhoea—Sorafenib—thyroid cancer	0.00409	0.00409	CcSEcCtD
Nadolol—Gastritis—Epirubicin—thyroid cancer	0.00398	0.00398	CcSEcCtD
Nadolol—Dizziness—Sorafenib—thyroid cancer	0.00395	0.00395	CcSEcCtD
Nadolol—Mood swings—Doxorubicin—thyroid cancer	0.00394	0.00394	CcSEcCtD
Nadolol—Abdominal distension—Epirubicin—thyroid cancer	0.00391	0.00391	CcSEcCtD
Nadolol—Dry skin—Doxorubicin—thyroid cancer	0.00381	0.00381	CcSEcCtD
Nadolol—Vomiting—Sorafenib—thyroid cancer	0.0038	0.0038	CcSEcCtD
Nadolol—Rash—Sorafenib—thyroid cancer	0.00377	0.00377	CcSEcCtD
Nadolol—Dermatitis—Sorafenib—thyroid cancer	0.00376	0.00376	CcSEcCtD
Nadolol—Gastritis—Doxorubicin—thyroid cancer	0.00368	0.00368	CcSEcCtD
Nadolol—Abdominal distension—Doxorubicin—thyroid cancer	0.00362	0.00362	CcSEcCtD
Nadolol—Nausea—Sorafenib—thyroid cancer	0.00355	0.00355	CcSEcCtD
Nadolol—Weight increased—Epirubicin—thyroid cancer	0.00353	0.00353	CcSEcCtD
Nadolol—Conjunctivitis—Epirubicin—thyroid cancer	0.00336	0.00336	CcSEcCtD
Nadolol—Sweating—Epirubicin—thyroid cancer	0.00332	0.00332	CcSEcCtD
Nadolol—Weight increased—Doxorubicin—thyroid cancer	0.00327	0.00327	CcSEcCtD
Nadolol—Agranulocytosis—Epirubicin—thyroid cancer	0.00323	0.00323	CcSEcCtD
Nadolol—Bradycardia—Epirubicin—thyroid cancer	0.00316	0.00316	CcSEcCtD
Nadolol—Conjunctivitis—Doxorubicin—thyroid cancer	0.00311	0.00311	CcSEcCtD
Nadolol—Sweating—Doxorubicin—thyroid cancer	0.00307	0.00307	CcSEcCtD
Nadolol—Visual impairment—Epirubicin—thyroid cancer	0.00299	0.00299	CcSEcCtD
Nadolol—Agranulocytosis—Doxorubicin—thyroid cancer	0.00299	0.00299	CcSEcCtD
Nadolol—Bradycardia—Doxorubicin—thyroid cancer	0.00293	0.00293	CcSEcCtD
Nadolol—Tinnitus—Epirubicin—thyroid cancer	0.0029	0.0029	CcSEcCtD
Nadolol—Visual impairment—Doxorubicin—thyroid cancer	0.00277	0.00277	CcSEcCtD
Nadolol—Alopecia—Epirubicin—thyroid cancer	0.00275	0.00275	CcSEcCtD
Nadolol—Tinnitus—Doxorubicin—thyroid cancer	0.00268	0.00268	CcSEcCtD
Nadolol—Flatulence—Epirubicin—thyroid cancer	0.00267	0.00267	CcSEcCtD
Nadolol—Vision blurred—Epirubicin—thyroid cancer	0.00255	0.00255	CcSEcCtD
Nadolol—Alopecia—Doxorubicin—thyroid cancer	0.00254	0.00254	CcSEcCtD
Nadolol—Flatulence—Doxorubicin—thyroid cancer	0.00247	0.00247	CcSEcCtD
Nadolol—Syncope—Epirubicin—thyroid cancer	0.00243	0.00243	CcSEcCtD
Nadolol—Loss of consciousness—Epirubicin—thyroid cancer	0.00238	0.00238	CcSEcCtD
Nadolol—Cough—Epirubicin—thyroid cancer	0.00236	0.00236	CcSEcCtD
Nadolol—Vision blurred—Doxorubicin—thyroid cancer	0.00236	0.00236	CcSEcCtD
Nadolol—Hypertension—Epirubicin—thyroid cancer	0.00234	0.00234	CcSEcCtD
Nadolol—Chest pain—Epirubicin—thyroid cancer	0.0023	0.0023	CcSEcCtD
Nadolol—Dry mouth—Epirubicin—thyroid cancer	0.00225	0.00225	CcSEcCtD
Nadolol—Syncope—Doxorubicin—thyroid cancer	0.00224	0.00224	CcSEcCtD
Nadolol—Oedema—Epirubicin—thyroid cancer	0.00221	0.00221	CcSEcCtD
Nadolol—Loss of consciousness—Doxorubicin—thyroid cancer	0.0022	0.0022	CcSEcCtD
Nadolol—Cough—Doxorubicin—thyroid cancer	0.00218	0.00218	CcSEcCtD
Nadolol—Shock—Epirubicin—thyroid cancer	0.00217	0.00217	CcSEcCtD
Nadolol—Hypertension—Doxorubicin—thyroid cancer	0.00216	0.00216	CcSEcCtD
Nadolol—Hyperhidrosis—Epirubicin—thyroid cancer	0.00213	0.00213	CcSEcCtD
Nadolol—Chest pain—Doxorubicin—thyroid cancer	0.00213	0.00213	CcSEcCtD
Nadolol—Anorexia—Epirubicin—thyroid cancer	0.0021	0.0021	CcSEcCtD
Nadolol—Dry mouth—Doxorubicin—thyroid cancer	0.00208	0.00208	CcSEcCtD
Nadolol—Hypotension—Epirubicin—thyroid cancer	0.00206	0.00206	CcSEcCtD
Nadolol—Oedema—Doxorubicin—thyroid cancer	0.00204	0.00204	CcSEcCtD
Nadolol—Shock—Doxorubicin—thyroid cancer	0.00201	0.00201	CcSEcCtD
Nadolol—Insomnia—Epirubicin—thyroid cancer	0.002	0.002	CcSEcCtD
Nadolol—Paraesthesia—Epirubicin—thyroid cancer	0.00198	0.00198	CcSEcCtD
Nadolol—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00197	0.00197	CcSEcCtD
Nadolol—Dyspnoea—Epirubicin—thyroid cancer	0.00197	0.00197	CcSEcCtD
Nadolol—Anorexia—Doxorubicin—thyroid cancer	0.00195	0.00195	CcSEcCtD
Nadolol—Dyspepsia—Epirubicin—thyroid cancer	0.00194	0.00194	CcSEcCtD
Nadolol—Decreased appetite—Epirubicin—thyroid cancer	0.00192	0.00192	CcSEcCtD
Nadolol—Hypotension—Doxorubicin—thyroid cancer	0.00191	0.00191	CcSEcCtD
Nadolol—Fatigue—Epirubicin—thyroid cancer	0.0019	0.0019	CcSEcCtD
Nadolol—Pain—Epirubicin—thyroid cancer	0.00189	0.00189	CcSEcCtD
Nadolol—Constipation—Epirubicin—thyroid cancer	0.00189	0.00189	CcSEcCtD
Nadolol—Insomnia—Doxorubicin—thyroid cancer	0.00185	0.00185	CcSEcCtD
Nadolol—Paraesthesia—Doxorubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Nadolol—Dyspnoea—Doxorubicin—thyroid cancer	0.00182	0.00182	CcSEcCtD
Nadolol—Dyspepsia—Doxorubicin—thyroid cancer	0.0018	0.0018	CcSEcCtD
Nadolol—Decreased appetite—Doxorubicin—thyroid cancer	0.00178	0.00178	CcSEcCtD
Nadolol—Fatigue—Doxorubicin—thyroid cancer	0.00176	0.00176	CcSEcCtD
Nadolol—Constipation—Doxorubicin—thyroid cancer	0.00175	0.00175	CcSEcCtD
Nadolol—Pain—Doxorubicin—thyroid cancer	0.00175	0.00175	CcSEcCtD
Nadolol—Body temperature increased—Epirubicin—thyroid cancer	0.00175	0.00175	CcSEcCtD
Nadolol—Body temperature increased—Doxorubicin—thyroid cancer	0.00161	0.00161	CcSEcCtD
Nadolol—Asthenia—Epirubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Nadolol—Pruritus—Epirubicin—thyroid cancer	0.00156	0.00156	CcSEcCtD
Nadolol—Diarrhoea—Epirubicin—thyroid cancer	0.00151	0.00151	CcSEcCtD
Nadolol—Asthenia—Doxorubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Nadolol—Dizziness—Epirubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Nadolol—Pruritus—Doxorubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Nadolol—Vomiting—Epirubicin—thyroid cancer	0.0014	0.0014	CcSEcCtD
Nadolol—Diarrhoea—Doxorubicin—thyroid cancer	0.0014	0.0014	CcSEcCtD
Nadolol—Rash—Epirubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Nadolol—Dermatitis—Epirubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Nadolol—Dizziness—Doxorubicin—thyroid cancer	0.00135	0.00135	CcSEcCtD
Nadolol—Nausea—Epirubicin—thyroid cancer	0.00131	0.00131	CcSEcCtD
Nadolol—Vomiting—Doxorubicin—thyroid cancer	0.0013	0.0013	CcSEcCtD
Nadolol—Rash—Doxorubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Nadolol—Dermatitis—Doxorubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Nadolol—Nausea—Doxorubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
